GAS5 and neoplasm: Analysis of the validation cohorts confirmed the reduced expression of GAS5 in HG tumours (Hedegaard et al., p = 0.050—PUNLMP not evaluated; Fig. 2e and TCGA, p < 0.001; Fig. 2f), and in advanced tumour stages (Hedegaard et al., p = 0.060; Fig. 2g).